OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

High CA-125 Levels: Causes, Normal Range and Cancer Risk

NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

ESMO 2026: What’s New in Melanoma Immunotherapy?

Sara Tolaney: Breast Cancer Insights From ESMO 2026

A National Multidisciplinary BC Course Has Trained 180 Clinicians Across Mongolia - UICC

Oncology News, Insights, Stories by OncoDaily

ESMO 2026 Presidential Symposia: From Trial Results to Clinical Implications
Oncolibrary

ESMO 2026 Presidential Symposia: From Trial Results to Clinical Implications

Salivary Gland Cancer
Radiotherapy

Phase II Trial Shows Promising Pathologic Responses With Neoadjuvant Nivolumab and Chemotherapy in Salivary Gland Cancer

Natera
OncoDaily Pulse

OncoDaily and Natera Present “Seismic Shift: Innovations in MRD Testing and Pathology”

What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment

Juliette Thariat: A Paradigm Shift in Oligometastatic Head and Neck Cancer

Glenn Balasky at COGC 2026: Why NGS Fails Without the Right Workflow

Palliative Care and End-of-Life Accompaniment in Oncology in Algeria: Ethical Reflection, Challenges of Palliative Sedation, and the Imperative of Interdisciplinary Collaboration

Julie Gralow։ ESMO - ASCO Joint Session Explored the Evolving Definition of the Modern Oncologist

Toufic Kachaamy: Neoadjuvant Immunotherapy is Changing Colorectal Cancer Care

Nicholas Hornstein: Key Insights From ESMO 2026

Voices
ECMC

ECMC Joins Early-Phase Consortia for the 4th CONNECT Meeting to Improve Access to Innovative Therapies

Fabrice Andre: Key Reflections on Innovation, Transformation and Community From ESMO 2026

Hongcheng Zhu: Hope Rugo Offers Guidance for Publishing in Oncology Journals

Brad Wouters: SHERLOCK Tracks 7,000 Patients to Detect Cancer Recurrence Earlier

Opportunity to Join Experts in the Immuno-Oncology Field at SITC Spring Scientific

Giannis Mountzios: Does Tarlatamab Provide Long Term Benefit to Responding Patients?

Pamela Abdayem: Had the Pleasure of Presenting 2 Abstracts on Lung Cancer Prevention at ESMO 2026

FDA Approvals
CLL/SLL Pirtobrutinib

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Niklas Klümper: FDA Approves Belzutifan Plus Lenvatinib in Advanced ccRCC

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Floretyrosine F 18 for PET Imaging in Glioma

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Celebrities and Cancer

OncoCalendar

2026 NCODA International Fall Summit

NCODA

28 Oct
NCODA International Fall Summit

Advancing Surgical Oncology in the Era of Multidisciplinary Cancer Care

Memorial Sloan Kettering Cancer Center (MSK)

28 Oct
Advancing Surgical Oncology

SPCC Webinar: Integrative Oncology from Biological Mechanisms to Clinical Impact

Sharing Progress in Cancer Care (SPCC)

28 Oct
SPCC

ESOI Touchdown 2026

European Society of Oncologic Imaging

29 Oct
ESOI Touchdown 2026

2026 IBRI Global Forum on Science, Philanthropy, and Investment

Indiana Biosciences Research Institute (IBRI)

29 Oct
IBRI Global forum

The IBRI Global Forum

Indiana Biosciences Research Institute (IBRI)

29 Oct
IBRI Global Forum

ESO Ambassador Event on Neoadjuvant and Post-Neoadjuvant Treatment in Breast Cancer

European School of Oncology (ESO) College

30 Oct
Breast Cancer

2026 Advances in Chronic Graft-Versus-Host Disease

Memorial Sloan Kettering Cancer Center (MSK)

30 Oct
Graft-Versus-Host Disease

London Global Cancer Week - LGCW 2026

London Global Cancer Week

02 Nov
Global Cancer Week

Rare Gynecologic Cancers: Advancing Knowledge through Collaboration in Research and Clinical Care

The University of Texas MD Anderson Cancer Center

02 Nov
Rare Gynecologic Cancers

L’Oncodaily Session During London Cancer Week 2026

London Global Cancer Week

02 Nov
L’Oncodaily Session

Chromosomes in Crisis: From Chromosomal Instability to Catastrophes in Cancer Genomes

European Association for Cancer Research

03 Nov
Chromosomes in Crisis

Immune-oncology
ESMO 2026: What’s New in Melanoma Immunotherapy?

ESMO 2026: What’s New in Melanoma Immunotherapy?

KEYNOTE-C93 Trial: Pembrolizumab Versus Chemotherapy in dMMR Endometrial Cancer

MOIO Trial: Can Immunotherapy Be Given Less Frequently?

KN035-CN-005 Trial: Envafolimab Plus GEMOX in Advanced Biliary Tract Cancer

PEARLS/KEYNOTE-091: Long-Term Outcomes With Adjuvant Pembrolizumab in NSCLC

DeLLphi-304 Trial: Tarlatamab Versus Chemotherapy in SCLC

Combi-TED Trial: OSE2101 Cancer Vaccine in Advanced NSCLC

Gastrointestinal-Oncology
NEOASIS

NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

OPTIMUM at ESMO 2026: Maintenance Olaparib With or Without Durvalumab in DDR-Mutated Advanced Biliary Tract Cancer

LEAP-012 at ESMO 2026: Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC

C-CAR031 at ESMO 2026 : Updated Results of GPC3-Targeted Armored CAR-T Therapy in Advanced HCC

Phase II HRS-4642 Plus Chemotherapy With or Without Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results at ESMO 2026

HARMONi-GI1 at ESMO 2026: Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer

CLARITY-Gastric 01 at ESMO 2026: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer

Breast-Oncology
esmo 2026

What Changes in Breast Oncology After ESMO 2026? The Trials, Treatment Shifts, and Unanswered Questions Shaping Clinical Practice

OptiTROP-Breast01 Final Analysis: Sacituzumab Tirumotecan Sustains Overall Survival Benefit in Previously Treated Metastatic Triple-Negative Breast Cancer

HR-Positive, HER2-Negative Breast Cancer in Algeria: Beyond Endocrine Therapy Alone

HER2-Positive Breast Cancer in Algeria: What Happens After Neoadjuvant Therapy?

PREDICT-HER: HER2-PET Identifies T-DXd Resistance Beyond Conventional HER2 Pathology

POP-DURVA: Short-Course Durvalumab Remodels the Immune Microenvironment but Rarely Produces pCR in Stage I TNBC

VIKTORIA-1: Gedatolisib Maintains Strong PFS Benefit in PIK3CA-Mutant Breast Cancer With Visceral Disease

Lung-Oncology
esmo 2026

What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment

ASTRIDE: Serplulimab Shows Numerically Longer Overall Survival Than Atezolizumab in US Patients With Extensive-Stage Small Cell Lung Cancer

SANOVO Phase III: Savolitinib Plus Osimertinib Significantly Prolongs First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC, With Strong Overall Survival Signal

MDT-BRIDGE: Early ctDNA Clearance Predicts Pathological Response and Favorable Outcomes in Stage II–III NSCLC

PEARLS/KEYNOTE-091 Final Analysis: Pembrolizumab Maintains Disease-Free Survival Benefit but Does Not Improve Overall Survival After Seven Years

Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

SAFFRON Phase III: Osimertinib Plus Savolitinib Significantly Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated NSCLC

OncoDaily TV
Dr Gevorg Tamamyan

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg Tamamyan’s WHO DG Campaign

Rachel Purcell

Rachel Purcell Highlights New Zealand’s Nationwide Exercise Program for Bowel Cancer Patients

Alicia Fong

Alicia Fong: Exploring the Role of AI in Cancer Detection and Treatment

Dr Gevorg Tamamyan

“Stronger Regions, Stronger Countries…” – Dr Gevorg Tamamyan

Rejin Kebudi

“Diligent, Intelligent, Capable of Reaching Many Colleagues Globally ” – Rejin Kebudi, General Secretary of the International Society of Pediatric Oncology, about Dr Gevorg Tamamyan Upon His WHO DG Candidacy

Dr. Gevorg Tamamyan

“One of the Most Amazing and Truly Legendary Oncologists of Our Time” – Dr. Gevorg Tamamyan on Dr. Julie Gralow, Chief Medical Officer of ASCO

Dr Gevorg Tamamyan

“I Still Remember His Mentees That Spoke So Highly of Him… Having a Vision Means Investing in People That Will Make a Difference For the Years to Come” – Albanian Hematologist Liri Seraj Supports Dr Gevorg Tamamyan as WHO DG Candidate

World Radiotherapy Awareness Day

12 Countries, One Vision for the Future of Radiotherapy – World Radiotherapy Awareness Day

Bishal Gyawali

Erika Ruiz-Garcia Joins Bishal Gyawali on Grounded In Groundshot Podcast

Dr Gevorg Tamamyan

“One Planet is Not Enough For His Vision” – Dr Amalya Sargsyan Celebrates Her Mentor Dr Gevorg Tamamyan

Dr Gevorg Tamamyan

Renowned Surgeon and Inventor of Abraxane, Philanthropist Dr Patrick Soon-Shiong Endorses Dr Gevorg Tamamyan as WHO Director-General Candidate

Burnout

Oncology Beyond Guidelines: Burnout, Imposter Syndrome, Mentorship & Cancer Prevention with Imène Hadji

Not To Miss
ESMO

25 Posts Not to Miss from ESMO Congress 2026: Day 5

25 Posts Not to Miss from ESMO Congress 2026: Day 4

25 Posts Not to Miss from ESMO Congress 2026: Day 3

20 Posts Not to Miss from ESMO Congress 2026: Day 2

20 Posts Not to Miss from ESMO Congress 2026: Day 1

UICC Announces New Board of Directors for 2026–2028

Zainab Shinkafi-Bagudu Assumes the Role of UICC President

OncoGrants
MRF

MRF Career Development Award 2027

Cancer Research Institute

Cancer Research Institute - Clinical Innovator Grant 2026–2027

Special Fellowship Funding

Yorkshire Cancer Research 2027 Special Fellowship Funding Round

Surgical Oncology

ESSO Educational Grants for Surgical Oncology 2026

Traditional Grant Program

Gateway for Cancer Research Traditional Grant Program 2026

CRI

CRI Technology Impact Award 2026

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Mintu Mathew Abraham

Mintu Mathew Abraham

Oncologists Location Mumbai, India
Abeid Athman Omar

Abeid Athman Omar

Oncologists Location Nairobi, Kenya
Rachna Shroff

Rachna Shroff

Oncologists Location Tucson, USA
Chandler Park

Chandler Park

Oncologists Location Louisville, USA
Roberto Carmagnani Pestana

Roberto Carmagnani Pestana

Oncologists Location São Paulo, Brazil
Joshua Brody

Joshua Brody

Oncologists Location New York, USA
Dilyara Kaidarova

Dilyara Kaidarova

Oncologists Location Almaty, Kazakhstan
Aadhya Tiwari

Aadhya Tiwari

Oncologists Location Houston, USA

Drugs Atlas
Pemigatinib (Pemazyre): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR-Driven Cancers and Myeloid/Lymphoid Neoplasms Pemigatinib (Pemazyre) Oct 28, 2026 1:02 am
Quizartinib (Vanflyta): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FLT3-ITD–Positive Acute Myeloid Leukemia Quizartinib (Vanflyta) Oct 26, 2026 2:27 am
Gilteritinib (Xospata): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Relapsed or Refractory FLT3-Mutated AML Gilteritinib (Xospata) Oct 26, 2026 1:34 am
Ruxolitinib (Jakafi): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease Ruxolitinib (Jakafi) Oct 24, 2026 1:00 pm
Midostaurin (Rydapt): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FLT3-Mutated AML and Advanced Systemic Mastocytosis Midostaurin (Rydapt) Oct 24, 2026 12:58 pm
Fedratinib (Inrebic): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Myelofibrosis Fedratinib (Inrebic) Oct 23, 2026 2:28 am
Ponatinib (Iclusig): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML and Philadelphia Chromosome-Positive ALL Ponatinib (Iclusig) Oct 23, 2026 2:03 am
Bosutinib (Bosulif): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Chronic Myeloid Leukemia Bosutinib (Bosulif) Oct 22, 2026 1:37 am
Nilotinib: Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Chronic Myeloid Leukemia Nilotinib Oct 22, 2026 1:35 am
Dasatinib (Sprycel): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in CML and Philadelphia Chromosome-Positive ALL Dasatinib (Sprycel) Oct 21, 2026 1:37 am

OncoDaily Magazine

New Paper Alert
Allan Pereira

Allan Pereira: MASTERPLAN Shows SBRT More Than Halves Locoregional Recurrence in Pancreatic Cancer

Nicholas Hornstein

Nicholas Hornstein: IROCAS Trial Finds No DFS Benefit From Adjuvant Irinotecan in High-Risk Colon Cancer

Jon Wigginton

Jon Wigginton: New Survival Data for Tarlatamab Plus Durvalumab Presented at ESMO 2026

Brian Slomovitz

Brian Slomovitz to Present KEYNOTE-C93 Phase 3 Results at ESMO 2026

Jennifer Bailey-Lundberg

Jennifer Bailey-Lundberg: New Findings on Tumor Immune Remodeling in PDAC

Vinidh Paleri

Vinidh Paleri: Study of Over 30,000 Patients Identifies Key Drivers of Head and Neck Cancer Treatment Delays

OncoDaily Medical Journal

GU Oncology

10.69690/ODMJ-001-1026-8269

Psychosocial burden and lifestyle impact in patients with renal cell carcinoma: a patient-reported outcomes analysis
Original Research

Pediatric Oncology

10.69690/ODMJ-001-1026-8309

Limited Prognostic Value of Baseline Curie Score in Children with High-Risk Neuroblastoma Treated with Contemporary Multi-modal Therapy: A Single-Center Retrospective Cohort Study
Original Research

Breast Cancer

10.69690/ODMJ-001-1026-8231

Variable-Volume Oncoplastic Reconstruction Using a Modified Würinger Central Pedicle Technique for Upper Quadrants Breast Cancer: a single-center experience
Original Research

GI Oncology

10.69690/ODMJ-001-1026-8138

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial
Original Research

Oncology Nursing

10.69690/ODMJ-002-0926-8087

Risk of Atrial Fibrillation in Breast Cancer Patients Treated with Radiotherapy: A Scoping Review
Reviews

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews